Cancer therapy-induced cardiac toxicity in early breast cancer: addressing the unresolved issues.
作者信息
Khouri Michel G, Douglas Pamela S, Mackey John R, Martin Miguel, Scott Jessica M, Scherrer-Crosbie Marielle, Jones Lee W
机构信息
Duke Cancer Institute, Box 3085, Durham, NC 27710, USA.
出版信息
Circulation. 2012 Dec 4;126(23):2749-63. doi: 10.1161/CIRCULATIONAHA.112.100560.
Abstract
摘要
相似文献
1
Cancer therapy-induced cardiac toxicity in early breast cancer: addressing the unresolved issues.早期乳腺癌中癌症治疗引起的心脏毒性：解决未解决的问题。
Circulation. 2012 Dec 4;126(23):2749-63. doi: 10.1161/CIRCULATIONAHA.112.100560.
2
Modulation of anthracycline-induced cardiotoxicity by aerobic exercise in breast cancer: current evidence and underlying mechanisms.有氧运动对乳腺癌患者蒽环类药物所致心脏毒性的调节作用：当前证据及潜在机制
Circulation. 2011 Aug 2;124(5):642-50. doi: 10.1161/CIRCULATIONAHA.111.021774.
3
4
Cardiological adverse events after oncological treatment in women.女性肿瘤治疗后的心脏不良事件
Przegl Lek. 2012;69(2):87-9.
5
Introduction to cardiotoxicity review series.心脏毒性综述系列介绍
Circ Res. 2010 Jan 8;106(1):19-20. doi: 10.1161/CIRCRESAHA.109.210724.
6
Drug-related cardiotoxicity for the treatment of haematological malignancies in elderly.老年血液系统恶性肿瘤治疗相关的心脏毒性。
Curr Pharm Des. 2010;16(26):2872-9. doi: 10.2174/138161210793176446.
7
Clinical vignettes: integrated care of cancer patients by oncologists and cardiologists.
Curr Cardiol Rev. 2011 Nov;7(4):258-61. doi: 10.2174/157340311799960654.
8
Cardiac risk associated with the receipt of anthracycline and trastuzumab in a large nationwide cohort of older women with breast cancer, 1998-2005.1998-2005 年，在一个大型全国范围内的老年乳腺癌女性队列中，蒽环类药物和曲妥珠单抗的使用与心脏风险相关。
Med Oncol. 2011 Dec;28 Suppl 1:S80-90. doi: 10.1007/s12032-010-9717-7. Epub 2010 Oct 22.
9
Preventing Today's Survivors of Breast Cancer From Becoming Tomorrow's Cardiac Patients.防止今日的乳腺癌幸存者成为明日的心脏病患者。
J Oncol Pract. 2018 Apr;14(4):213-214. doi: 10.1200/JOP.18.00130.
10
Alcohol and HER2 polymorphisms as risk factor for cardiotoxicity in breast cancer treated with trastuzumab.酒精和 HER2 多态性作为曲妥珠单抗治疗乳腺癌中心脏毒性的危险因素。
Anticancer Res. 2013 Jun;33(6):2569-76.
引用本文的文献
1
The crosstalk of breast cancer and ischemic heart disease.乳腺癌与缺血性心脏病的相互影响
Cell Death Discov. 2025 Apr 18;11(1):185. doi: 10.1038/s41420-025-02428-6.
2
Cardiotoxicity in patients with metastatic melanoma treated with BRAF/MEK inhibitors: a real-world analysis of incidence, risk factors, and reversibility.接受BRAF/MEK抑制剂治疗的转移性黑色素瘤患者的心脏毒性：发病率、危险因素及可逆性的真实世界分析
Acta Oncol. 2025 Apr 13;64:507-515. doi: 10.2340/1651-226X.2025.42567.
3
Genetic analysis reveals the shared genetic architecture between breast cancer and atrial fibrillation.基因分析揭示了乳腺癌和心房颤动之间共享的遗传结构。
Front Genet. 2025 Mar 25;16:1450259. doi: 10.3389/fgene.2025.1450259. eCollection 2025.
4
Association Between Advanced TNM Stages and Increased Risk of Cardiac Dysfunction in Patients with LVEF < 50.左心室射血分数（LVEF）<50%的患者中，晚期TNM分期与心脏功能障碍风险增加之间的关联。
Medicina (Kaunas). 2025 Feb 10;61(2):301. doi: 10.3390/medicina61020301.
5
New insights into mitochondrial quality control in anthracycline-induced cardiotoxicity: molecular mechanisms, therapeutic targets, and natural products.蒽环类药物诱导的心脏毒性中线粒体质量控制的新见解：分子机制、治疗靶点和天然产物。
Int J Biol Sci. 2025 Jan 1;21(2):507-523. doi: 10.7150/ijbs.103810. eCollection 2025.
6
Cardiotoxicity in Breast Cancer: Impact of Clinical Classifications and Treatment on Heart Health.乳腺癌中的心脏毒性：临床分类和治疗对心脏健康的影响。
Cancers (Basel). 2024 Dec 23;16(24):4281. doi: 10.3390/cancers16244281.
7
High-Intensity Interval Training for Cancer Patients: A Review of Key Considerations for Exercise Prescription.癌症患者的高强度间歇训练：运动处方的关键考虑因素综述
Sports Med. 2025 Mar;55(3):619-639. doi: 10.1007/s40279-024-02145-7. Epub 2024 Nov 27.
8
Comparative efficacy of anthracycline-free and anthracycline-containing neoadjuvant chemoimmunotherapy regimens for triple-negative breast cancer.蒽环类药物-free和含蒽环类药物的新辅助化疗免疫治疗方案对三阴性乳腺癌的疗效比较
Transl Oncol. 2025 Jan;51:102171. doi: 10.1016/j.tranon.2024.102171. Epub 2024 Nov 1.
9
Unveiling the Mechanism of Protective Effects of Tanshinone as a New Fighter Against Cardiovascular Diseases: A Systematic Review.揭示丹参酮作为心血管疾病新斗士的保护作用机制：系统评价。
Cardiovasc Toxicol. 2024 Dec;24(12):1467-1509. doi: 10.1007/s12012-024-09921-x. Epub 2024 Sep 22.
10
Real-World Cardiotoxicity in Metastatic Melanoma Patients Treated with Encorafenib and Binimetinib.恩考芬尼和比美替尼治疗转移性黑色素瘤患者的真实世界心脏毒性
Cancers (Basel). 2024 Aug 23;16(17):2945. doi: 10.3390/cancers16172945.
本文引用的文献
1
Screening adult survivors of childhood cancer for cardiomyopathy: comparison of echocardiography and cardiac magnetic resonance imaging.筛查成年癌症幸存者的心肌病：超声心动图与心脏磁共振成像的比较。
J Clin Oncol. 2012 Aug 10;30(23):2876-84. doi: 10.1200/JCO.2011.40.3584. Epub 2012 Jul 16.
2
Cardiopulmonary function and age-related decline across the breast cancer survivorship continuum.乳腺癌生存者全周期的心肺功能与年龄相关衰退。
J Clin Oncol. 2012 Jul 10;30(20):2530-7. doi: 10.1200/JCO.2011.39.9014. Epub 2012 May 21.
3
Trastuzumab containing regimens for early breast cancer.含曲妥珠单抗的早期乳腺癌治疗方案。
Cochrane Database Syst Rev. 2012 Apr 18;2012(4):CD006243. doi: 10.1002/14651858.CD006243.pub2.
4
Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies.多柔比星诱导性心肌病：从分子机制到治疗策略。
J Mol Cell Cardiol. 2012 Jun;52(6):1213-25. doi: 10.1016/j.yjmcc.2012.03.006. Epub 2012 Mar 21.
5
BRCA2 protein deficiency exaggerates doxorubicin-induced cardiomyocyte apoptosis and cardiac failure.BRCA2 蛋白缺乏症加剧阿霉素诱导的心肌细胞凋亡和心力衰竭。
J Biol Chem. 2012 Feb 24;287(9):6604-14. doi: 10.1074/jbc.M111.292664. Epub 2011 Dec 8.
6
Adjuvant trastuzumab in HER2-positive breast cancer.曲妥珠单抗辅助治疗 HER2 阳性乳腺癌。
N Engl J Med. 2011 Oct 6;365(14):1273-83. doi: 10.1056/NEJMoa0910383.
7
Pretreatment and routine echocardiogram monitoring during chemotherapy for anthracycline-induced cardiotoxicity rarely identifies significant cardiac dysfunction or alters treatment decisions: a 5-year review at a single pediatric oncology center.在蒽环类药物引起的心脏毒性的化疗期间进行预处理和常规超声心动图监测很少能发现明显的心脏功能障碍或改变治疗决策：单一儿科肿瘤中心的 5 年回顾。
Cancer. 2012 Apr 1;118(7):1919-24. doi: 10.1002/cncr.26481. Epub 2011 Aug 31.
8
Efficiency of atorvastatin in the protection of anthracycline-induced cardiomyopathy.阿托伐他汀在保护蒽环类药物诱导的心肌病方面的疗效。
J Am Coll Cardiol. 2011 Aug 23;58(9):988-9. doi: 10.1016/j.jacc.2011.05.025.
9
Inhibition of Rac1 signaling by lovastatin protects against anthracycline-induced cardiac toxicity.洛伐他汀通过抑制 Rac1 信号转导来预防蒽环类抗生素诱导的心脏毒性。
Cell Death Dis. 2011 Aug 11;2(8):e190. doi: 10.1038/cddis.2011.65.
10
Modulation of anthracycline-induced cardiotoxicity by aerobic exercise in breast cancer: current evidence and underlying mechanisms.有氧运动对乳腺癌患者蒽环类药物所致心脏毒性的调节作用：当前证据及潜在机制
Circulation. 2011 Aug 2;124(5):642-50. doi: 10.1161/CIRCULATIONAHA.111.021774.
Zotero 插件